José Luis Uriegas, CEO, Grupo Idesa

GBR Connect Series Grupo Idesa has adjusted to Mexico’s energy reforms and is exploring opportunities upstream. Grupo Idesa was founded in 1956. Could you provide an overview of the company and its focus areas today? The company started with the production of phthalic anhydride in a small plant and after that grew through different petrochemical complexes, first in Puebla, then in Tlaxcala and the latest complex we have is in Coatzacoalcos, in southern Veracruz State. Coatzacoalcos is well located as it is near to a lot of feedstock supplies. Here we buy ethylene oxide and ammonia from Peme...

Edison Terra Filho, Executive Vice President, Braskem

GBR Connect Series Braskem defines its strategy going forwards. Braskem is the largest petrochemical company in the Americas and the largest producer of thermoplastic resins in the region. What are the reasons for its success? It is due to the culmination of our consolidating of the market in Brazil, combined with the opportunity to purchase assets in the United States and our commitment to serving customers with products and services that they really need. We started our mission to consolidate the Brazilian petrochemicals industry in 2002 and finished the process by 2010. Braskem believed th...

    India Pharmaceuticals 2017

    Country: India • Industry: Pharmaceuticals • Publication: Global Business Reports • Release Date: November 2017 • Authors: Catherine Howe and Neha Premjee Executive Summary: India’s pharmaceutical industry, ranked third worldwide in terms of volume, is the largest supplier of generic drugs globally and a proponent of high-quality affordable medicines. The industry has posted double-digit growth over the last few years, rising to US$36.7 billion and projected to grow to US$40 billion by 2020. However, as price erosion continues to impact the market and competition increases, many...

    Akshay Singh, Managing Director, SGD Pharma India

    Cogent Glass, recently acquired by SGD Pharma, is a manufacturer of Type I moulded and tubular glass vials for the pharmaceutical industry How has Cogent Glass developed, particularly now as a division of SGD following the acquisition?  SGD Pharma India (Cogent Glass) has grown significantly over the last few years with an average CAGR of 34%  from 2013 to 2017. This is very promising when compared to the CAGR of pharmaceutical companies in India, which is at about 16%. The rebranding from Cogent to SGD was significant as SGD is the world leader in pharmaceutical glass packaging. Although a...

      Naresh Raisinghani, CEO & Executive Director, BMGI India

      BMGI India offers expertise is improving efficiencies in strategy, innovation, problem solving and business transformation. BMGI India operates across many different industries and as part of a global company. Could you briefly introduce BMGI India and outline the importance attributed to the pharmaceutical sector?  BMGI is sector agnostic and operates four service lines. One is strategic planning and strategy deployment, whereby the company assists large firms in deploying their strategies. The second is innovation, assisting firms in deploying innovation practices. The third line is proble...

      Raising the bar: India’s generic players compete for market share

      As India’s domestic pharmaceutical market becomes increasingly crowded and the industry as a whole continues along the path of globalization, expansion of geographic presence and diversification of customer portfolios is a core focus for most companies. Catherine Howe While India’s domestic generic drug market reached US$ 26.1 billion in 2016, the country’s top companies, according to Pharmexcil, meet 80% of domestic demand. These are also the country’s most prominent exporters to the regulated markets. (more…) ...

      Brazil Petrochemicals and Chemicals 2017

      Country: Brazil • Industry: Chemicals • Publication: Global Business Reports • Release Date: November 2017 • Authors: Laura Brangwin and Matthias Lomas Executive Summary: It was all going so well for Brazil in the years leading up to 2014. The economy was strong, with GDP growth reaching heady heights at 7.5% in 2010 and averaging 3% until 2014. As many developed countries were still reeling from the global financial crisis, Brazil, a member of the BRICS nations of emerging economies, appeared ascendant. In 2014, however, Brazil’s economy hit the rocks. What ensued was Brazil’...

      Harish Shah, Managing Director, Signet

      Signet is India’s largest excipient company with extensive activities extending to Bangladesh and the Middle East. Signet reached its 30th anniversary last year and is India’s largest excipient company. How prominent is the company in the market today? Signet experienced 20% to 25% growth each year from 2007 to 2015 but is currently posting growth at 13% to 15%. For FY 2016 to 2017, it has achieved a turnover of Rs.1150 cr US$177 million.  In the last three years, the market has plateaued somewhat because the Indian pharmaceutical industry has been under duress. As a result, exports to t...

      Building Blocks: Bulk Drugs, Excipients and Intermediates

      The largest supplier of generic drugs globally, India continues to fortify its reputation as a hub for the production of affordable quality medicines. Catherine Howe India’s strength in pharmaceutical formulations depends on a high-quality, cost-efficient and reliable supply of the required raw materials and building blocks. Whilst India has strong capabilities in active pharmaceutical ingredients (APIs), the domestic market has become increasingly crowded, marked by a heavy reliance on imports from China. “India had to manufacture the drugs that were remunerative for the country,” exp...

      More articles